Metabolic and hepatic effects of semaglutide and empagliflozin on metabolic dysfunction-associated steatotic liver disease mice
It has been hypothesised that the amelioration of MASLD by semaglutide and empagliflozin may be associated with a decrease in the levels of several LPCs in liver tissue.
Authors
- Chenxi Wang (ORCID: https://orcid.org/0000-0003-3508-4120)
- Lin Yue
- Shu Niu
- Shuqi Wang (ORCID: https://orcid.org/0000-0002-5764-8161)
- Shuchun Chen (ORCID: https://orcid.org/0000-0002-7747-3901)
Institutions
- Hebei General Hospital (CN)
Publication Details
- Journal
- World Journal of Hepatology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.4254/wjh.v17.i10.110402
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00